AstraZeneca’s Subcutaneous Saphnelo Shows Significant Disease Reduction in Landmark Lupus Trial

Group 1 - AstraZeneca is considered one of the best long-term stocks to buy, with Barclays analyst James Gordon raising the price target from 14,000 GBp to 16,500 GBp while maintaining an Overweight rating [1] - AstraZeneca published positive results from the Phase III TULIP-SC trial, showing that subcutaneous administration of Saphnelo significantly reduces disease activity in systemic lupus erythematosus patients, which is crucial for the 3.4 million people globally affected by this condition [2] - The trial demonstrated that weekly 120 mg subcutaneous doses of Saphnelo were well tolerated, with a safety profile similar to the intravenous version, and the new formulation is currently under regulatory review in the US and Japan [3] Group 2 - AstraZeneca is a biopharmaceutical company involved in the discovery, development, manufacturing, and commercialization of prescription medicines [4]